Filing Analysis
Wellgistics Health, Inc. entered into a forbearance agreement with Marco Capital, Inc. regarding approximately $1.77 million in outstanding debt. The agreement requires bi-weekly payments and imposes a high interest rate while providing only a short-term reprieve through June 15, 2026.
Red Flags
- Existence of a forbearance agreement indicates a prior default or inability to meet original loan terms.
- Very high interest rate (SOFR + 11.5%) typical of distressed debt.
- Short forbearance window (approx. 6 weeks) suggests immediate liquidity crisis.
- Personal guaranties from management (Prashant Patel and Eric Sherb) increase risk profile.
- Mandatory sweep of future financing proceeds limits the company's ability to use new capital for operations.
Key Facts
- Acknowledged $1.77 million in outstanding debt under a November 2024 Loan and Security Agreement.
- Forbearance period is extremely short, expiring on June 15, 2026.
- Interest rate set at Term SOFR plus 11.5% per annum starting May 5, 2026.
- Required bi-weekly payments of $50,000 beginning May 5, 2026.
- Net proceeds from future financing transactions must be partially applied to the debt repayment.
- Management members Prashant Patel and Eric Sherb reaffirmed personal guaranties.
Wellgistics Health (WGRX) entered into a Collaboration Agreement with Kare Rx Hub to form a joint venture, Healthstar Technologies, LLC, in which WGRX will hold a 51% interest. The company will acquire intellectual property assets for $2 million, payable in common stock, with a share reconciliation provision scheduled for April 2027.
Red Flags
- Potential for significant future dilution due to the price-based share reconciliation clause on April 1, 2027, which acts as a floorless reset.
- Discrepancy in dates: Agreement signed April 13, 2026, but closing mentioned as occurring on or about April 10, 2026.
Key Facts
- WGRX acquires 51% membership interest in newly formed Healthstar Technologies, LLC.
- Total consideration is $2,000,000 in unregistered common stock.
- Initial issuance of 1,500,000 shares at closing.
- A 'Reconciliation Date' of April 1, 2027, allows for additional share issuance to ensure the $2M value is met based on a 2-day VWAP.
- Shares are subject to a 12-month lock-up period.
Wellgistics Health, Inc. terminated a Settlement Agreement with Silverback Capital Inc. that facilitated debt-for-equity swaps under Section 3(a)(10). The company issued 6,866,000 shares prior to termination and is ending the arrangement to prevent further dilution and pursue alternative financing.
Red Flags
- Reliance on Section 3(a)(10) share issuances, which are often highly dilutive and used by companies in financial distress.
- Significant share issuance (6.86M shares) occurred in a very short window (approximately 2 months).
- Sudden termination of a material financing structure suggests a shift in strategy or potential friction with the settlement terms.
Key Facts
- Termination notice delivered to Silverback Capital Inc. on April 3, 2026.
- The original Settlement Agreement and Stipulation was dated January 28, 2026.
- A total of 6,866,000 shares of common stock were issued under the agreement prior to its termination.
- The agreement utilized Section 3(a)(10) of the Securities Act of 1933 for share issuance.
- Silverback Capital Inc. has been requested to return all rights and interests in unpaid claims to the original creditors.
Wellgistics Health, Inc. entered into a Note Purchase Agreement to raise $1,000,000 in cash through the issuance of $1,250,000 in promissory notes, representing a 20% original issue discount. The notes mature in 12 months or upon the closing of a qualified financing and carry restrictive covenants against additional debt.
Red Flags
- High cost of capital: 20% original issue discount for a 12-month term.
- Restrictive covenants: The company cannot incur additional debt or liens, which may severely limit operational flexibility if cash needs exceed the $1M raised.
- Potential for dilution: Investors have participation rights in future offerings for up to 100% of their principal.
Key Facts
- Note Purchase Agreement dated April 1, 2026, for up to $1,250,000 in aggregate principal.
- Investors paid an aggregate purchase price of $1,000,000, reflecting a 20% original issue discount (OID).
- Notes carry a 0% interest rate, increasing to 15% only in the event of default.
- Maturity is set for the 12-month anniversary of issuance or the closing of the next 'Qualified Financing'.
- Investors receive a right to participate in future offerings up to 100% of their note principal for at least one year.
- The company is prohibited from incurring new debt or granting liens while the notes are outstanding.
Wellgistics Health, Inc. entered into a 36-month Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC to distribute the 'KARE Verify' benefits verification product. The agreement provides for a 50/50 net revenue split between the two companies.
Key Facts
- Agreement signed on March 6, 2026, with Kare PharmTech LLC.
- Product involved is 'KARE Verify,' which provides benefits and eligibility verification services.
- Wellgistics will utilize its pharmacy, manufacturer, and distribution channels, including telemedicine platforms, for marketing.
- Net revenue will be shared equally (50% each) between the Company and PharmTech.
- The agreement has a standard term of 36 months unless terminated earlier.
Wellgistics Health, Inc. issued a press release on March 9, 2026, regarding the company's projects, potential financial performance, and growth opportunities. The information was furnished under Item 7.01 and is not considered filed for regulatory liability purposes.
Key Facts
- Press release issued and furnished on March 9, 2026
- Company is classified as an emerging growth company
- Common stock is listed on The Nasdaq Capital Market under the symbol WGRX
- Reference made to a Registration Statement on Form S-1 that became effective on September 25, 2025